Tanabe Pharma Corporation

This study tested a new drug called MP-424 combined with two standard medications (peginterferon alfa-2b and ribavirin) in 108 adults with genotype 2 hepatitis C whose previous treatment failed. The goal was to see if this combination could clear the virus completely, measured by…

This study tested a new vaccine called BK1310 in 33 healthy infants to see if it is safe and helps their bodies build protection against several diseases. The vaccine is given as a shot into the muscle. The main goal was to measure the number of infants who developed enough antib…

This study tested a new vaccine called MT-2301 to protect healthy infants against Haemophilus influenzae type b (Hib) disease. The vaccine was given alongside routine DPT-IPV shots, and its safety and ability to produce protective antibodies were compared to an existing Hib vacci…

This study tested a booster dose of the DTaP vaccine (BK1301) in 446 adolescents aged 11-12 who had already received 3 or 4 doses as children. The goal was to confirm the vaccine safely boosts protection against diphtheria, tetanus, and pertussis (whooping cough). Results showed …

This study looked at the long-term safety of a drug called MCI-196 in 116 adults with advanced kidney disease who are on dialysis and have high phosphate levels. The goal was to see if the drug is safe to take over time and if it helps control phosphate levels. Participants took …

This study tested a drug called MCI-196 in 642 adults on dialysis who had high phosphorus and cholesterol levels. The goal was to see if the drug could safely lower these levels, which are linked to heart problems. Participants took either MCI-196 or a placebo for 12 weeks after …

This study tested a medication called TA-7284 in over 1,200 Japanese adults with type 2 diabetes to see if it is safe and helps control blood sugar over a full year. Participants took the drug alone or with other diabetes medicines. The main goals were to track side effects and b…

This study tested an experimental daily pill (TA-7284) in 383 adults with type 2 diabetes to see if it safely lowers blood sugar and helps with weight. Participants took either the drug or a placebo for several weeks. The main goal was to measure changes in HbA1c (average blood s…

This study tested a drug called MCI-186 (edaravone) in 181 people with ALS, a serious nerve disease that weakens muscles over time. The goal was to see if the drug could slow down the disease and keep patients functioning longer. Participants received either the drug or a placebo…

This study tested a drug called MCI-186 in 36 adults who had a recent ischemic stroke (a clot blocking blood flow to the brain). The main goal was to check if the drug is safe and how the body processes it. Participants received the drug or a placebo within 1 to 24 hours after th…

This study tested a drug called MCI-196 in 245 adults on dialysis with high phosphorus levels. After a 12-week dose adjustment period, some patients switched to a placebo to see if MCI-196 kept phosphorus levels lower. The goal was to manage a common complication of kidney failur…

This study tested a new drug, MT-6548, against a standard treatment (darbepoetin alfa) for anemia in 304 people with chronic kidney disease who were not on dialysis. The goal was to see if MT-6548 could raise and maintain hemoglobin levels safely. Participants either switched fro…

This study tested a drug called teneligliptin in 254 Chinese adults with type 2 diabetes. The goal was to see if it safely lowers blood sugar levels over 24 weeks compared to a placebo. Participants took the drug or a dummy pill, and researchers measured changes in HbA1c and fast…

This study tested a new once-daily pill called MP-513 (Teneligliptin) in 324 Japanese adults with type 2 diabetes. The goal was to see if it safely lowers blood sugar levels (HbA1c) over 12 weeks compared to a placebo. Participants were on diet and exercise alone before starting …

This study tested three doses of a blood thinner called argatroban, given with standard anti-clotting drugs, in 140 people undergoing elective heart stent procedures. The goal was to see how well it prevents blood clots and bleeding compared to the usual blood thinner, heparin. P…

This early study tested the drug MT-2990 in 5 adults with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to explore how well the drug works, its safety, and how it acts in the body. Because this was a very small, exploratory…

This study looked at the long-term safety and effectiveness of adding canagliflozin to insulin therapy in people with type 2 diabetes. It included 139 adults who had already completed a 16-week study. Researchers monitored side effects, blood sugar control, and weight changes ove…

This study tested a drug called TA-650 in 31 children with Kawasaki disease whose fever did not go away after standard treatment. The goal was to see if TA-650 could safely reduce fever and prevent heart problems better than another drug. The results help doctors find better opti…

This study tested a lower dose (0.6 mg/kg) of the clot-dissolving drug alteplase in 103 Japanese patients who had a stroke caused by a blood clot. The goal was to see if this dose was both safe and effective when given within 3 hours of stroke symptoms starting. The trial measure…

This study tested a new medicine called MP-513 in 99 Japanese adults with type 2 diabetes. The goal was to see how well it controls blood sugar levels over 4 weeks. Participants took the drug and had their glucose measured after meals and throughout the day.

This study tested a drug called TA-650 (similar to infliximab) in 14 children with moderate to severe Crohn's disease. The goal was to see if the drug could reduce disease activity and improve symptoms. Children received the drug by infusion at regular intervals over nearly a yea…

This study tested a new medication called TA-7284 in 272 adults with type 2 diabetes. The goal was to see if the drug can safely lower blood sugar levels over 24 weeks compared to a placebo. Participants took the pill alone without other diabetes medicines.

This study compared two medications, edaravone and ozagrel, for treating acute ischemic stroke. It included 401 adults who started treatment within 24 hours of their stroke. The main goal was to see how many patients had a good recovery (little to no disability) after 3 months. T…

This study looked at the safety of an oral form of edaravone for people with ALS, a progressive nerve disease. Fifteen patients who completed earlier studies took the medicine for 10 days every two weeks. Researchers tracked side effects to see if the drug is safe for long-term u…

This study tested whether adding canagliflozin to teneligliptin helps Japanese adults with type 2 diabetes who are not well controlled on teneligliptin alone. 138 participants took the combination daily for 24 weeks. The main goal was to see if it lowered blood sugar levels (HbA1…

This study tested a medicine called TA-650 (similar to infliximab) in 21 children with moderate to severe ulcerative colitis, a disease causing inflammation in the colon. The goal was to see if the drug could reduce symptoms and help children feel better. Children received the dr…

This study tested whether adding teneligliptin to metformin helps Chinese adults with type 2 diabetes control their blood sugar better than metformin alone. 247 participants took either the combination or a placebo for 24 weeks. The main goal was to see changes in HbA1c, a key bl…

This study tested a drug called TA-650 (similar to infliximab) in 18 people with Behcet's disease who had serious complications like eye, brain, or gut problems that didn't get better with standard treatments. The drug was given as an IV infusion at weeks 0, 2, and 6, then every …

This study tested the long-term safety and effectiveness of the drug MP-513 (Teneligliptin) in 462 Japanese adults with type 2 diabetes. Participants took the drug alone or with other diabetes pills for 52 weeks. The main goal was to track side effects, and researchers also measu…

This study tested a once-daily combination pill (MT-2412) containing two diabetes drugs, Teneligliptin and Canagliflozin, in 153 Japanese adults with type 2 diabetes whose blood sugar was not well controlled on Teneligliptin alone. Over 52 weeks, researchers monitored safety and …

This study looked at the long-term safety and tolerability of the drug MP-214 in 254 adults with schizophrenia. Participants had already completed an earlier study and continued taking MP-214 to see how well it was tolerated over time. The main focus was on tracking any side effe…

This study tested a new drug called MP-424 combined with two standard hepatitis C medications (PEG-IFN and RBV) in 54 adults with genotype 1 hepatitis C who were either new to treatment or had relapsed after previous therapy. The main goal was to see if the virus could be cleared…

This study tested a new drug called MP-424 combined with two standard medicines (interferon beta and ribavirin) in 74 adults with chronic hepatitis C (genotype 1 or 2). The goal was to see if the combination could make the virus undetectable in the blood 24 weeks after treatment …

This study tested a new drug called MP-424 combined with two standard hepatitis C medications (peginterferon alfa-2b and ribavirin) in 10 adults with genotype 2 hepatitis C who had not responded to earlier treatment. The main goal was to see if the virus could be cleared from the…

This study tested an experimental drug called MCI-196 in 183 adults with type 2 diabetes. For 12 weeks, some participants received the drug and others received a placebo (a dummy pill). The goal was to see if the drug could lower blood sugar and improve cholesterol levels safely.…

This study tested a new drug called MCI-196 against a common statin (simvastatin) and a placebo to see how well it lowers LDL cholesterol in people with advanced chronic kidney disease on dialysis. About 260 adults on stable dialysis took part. The goal was to manage cholesterol …

This study tested whether a drug called MCI-186 can slow the progression of ALS, a serious nerve disease that weakens muscles over time. About 200 people with ALS received either the drug or a placebo daily for 24 weeks. Researchers measured changes in physical function to see if…

This study looked at the long-term safety and effectiveness of an investigational drug called MP-214 in 42 adults with schizophrenia who were already taking one or more antipsychotic medications. The main goal was to track any side effects over time. The study did not aim to cure…

This study tested whether adding teneligliptin to canagliflozin helps Japanese adults with type 2 diabetes who still have high blood sugar despite taking canagliflozin alone. Over 24 weeks, 154 participants took both drugs once daily. The main goal was to see if the combination l…

This study tested the long-term safety of a drug called MCI-196 in 632 adults with chronic kidney disease on dialysis who also have high phosphorus levels. Participants took the drug for up to 52 weeks to see how it affected their blood phosphorus and cholesterol. The goal was to…

This study tested a pill called MT-6548 in 24 adults in Japan who have anemia due to chronic kidney disease and are on hemodialysis. The goal was to see if the drug can safely raise and maintain their hemoglobin levels within a target range. Participants were not using other anem…

This study looked at how well the drug argatroban works in people with a rare blood condition called heparin-induced thrombocytopenia Type II, where blood clots form after using heparin. Twenty adults who needed blood-thinning treatment took part. The goal was to track deaths, ne…

This study tested a drug called MCI-186 in 137 people with ALS, a nerve disease that weakens muscles over time. Participants received daily IV infusions of the drug or a placebo for 24 weeks. The goal was to see if MCI-186 could slow the disease's progression, measured by a scale…

This study looked at whether a higher dose (10 mg/kg) of the drug TA-650 (also known as infliximab) could help people with Crohn's disease who were not getting enough benefit from the standard dose. The 39 participants received the higher dose every 8 weeks, and researchers track…

This study tested a daily pill called MT-5199 to see if it could reduce symptoms of tardive dyskinesia, a condition that causes uncontrollable movements of the face, mouth, arms, legs, and trunk. The study involved 256 adults with moderate to severe tardive dyskinesia who also ha…

This study tested a medicine called TAU-284 in 473 children aged 7 to 15 with year-round allergic rhinitis (nasal allergies). The goal was to see if it reduces sneezing, runny nose, and stuffiness better than a placebo over two weeks. The trial also checked for side effects.

This study tested an experimental drug called MT-8554 to see if it can safely reduce pain in people with diabetic nerve damage. 156 adults with long-lasting pain took either the drug or a placebo for 12 weeks. The main goal was to measure changes in average daily pain scores.

This study tested a new drug called TAU-284 in 490 children aged 7 to 15 who have year-round nasal allergies (perennial allergic rhinitis). The goal was to see if the drug reduces sneezing, runny nose, and stuffiness better than a placebo over two weeks. Researchers also checked …

This study tested an experimental drug called MT-8554 in 61 adults with painful diabetic peripheral neuropathy, a common complication of diabetes causing nerve pain. The goal was to see if the drug safely reduces pain compared to a placebo. Participants took the drug or placebo i…

This study looked at how a new drug called MP-214 works in 38 adults with schizophrenia. Researchers measured safety, how the drug moves through the body, and whether it helps control symptoms over 12 weeks. The goal was to find the right dose and check for side effects.

This early-stage study tested a new drug called MT-8554 in 24 women who have frequent hot flashes (at least 7 per day). The goal was to check the drug's safety and how the body processes it. Participants included women with breast cancer or those going through menopause. The stud…

This study tested if a medication called TAU-284 was as good as an existing drug (ketotifen) at reducing itch in children with atopic dermatitis, also known as eczema. Over 300 children, aged 7 to 15, took part in this two-week, double-blind trial. The main goal was to see if the…

This study looked at how the drug edaravone enters the bloodstream when given as a liquid by mouth or through a nasogastric tube. Thirty-six healthy Japanese adults took a single dose in a crossover design. The goal was to see if both methods deliver the drug similarly and to che…

This study looked at how eating different types of meals changes the way the body absorbs and processes an oral form of edaravone. Sixteen healthy Japanese adults took the drug under various meal conditions, including fasting. The goal was to gather information, not to treat any …

This study looked at how the drug MCI-186 is processed in people with mild or moderate liver problems compared to healthy people. A total of 22 adults received a single dose of the drug through an IV. The goal was to see if liver function changes how the drug moves through the bo…

This early-stage study tested an oral version of edaravone in 74 healthy adult men to see how the body processes it and if it is safe. Participants took single or multiple doses of the drug as a solution or suspension. The goal was to gather information on side effects and drug l…

This early-stage study looked at how an oral form of edaravone interacts with other common drugs and how it behaves in the body. It involved 84 healthy adult Japanese and Caucasian men. The goal was to gather safety and drug interaction data, not to treat any disease.

This study tested whether an oral liquid version of edaravone works the same as the intravenous (IV) version in 42 healthy Japanese adults aged 20 to 45. Participants received a single dose of each form, and researchers measured drug levels in the blood to compare absorption. The…

This study looked at how a new drug called MT-8554 changes the way the body processes two common cholesterol-lowering medicines, simvastatin and rosuvastatin. It involved 28 healthy men aged 18 to 55. The goal was to see if MT-8554 affects the levels of these statins in the blood…

This study looked at how the experimental drug TA-7284 behaves in people with type 2 diabetes who also have moderate kidney impairment. Researchers measured drug levels in the blood and urine, and checked for side effects. The goal was to understand how kidney function affects th…

This study tested whether MCI-186, an experimental drug, changes the heart's electrical activity (QT interval) in 27 healthy adult men. Participants received a low dose, a high dose, and a placebo on separate days. The goal was to see if the drug causes heart rhythm issues, helpi…

This study looked at how the drug MCI-186 moves through the body in people with severe liver damage compared to healthy people. Researchers gave a single dose to 12 adults and measured drug levels and side effects. The goal was to understand if liver problems change how the drug …